Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled Asthmatics
Authors:
- Elisabetta PaceEPElisabetta Pace
- Maria FerraroMFMaria Ferraro
- Andreina BrunoABAndreina Bruno
- Giuseppina ChiapparaGCGiuseppina Chiappara
- Jean BousquetJBJean Bousquet
- Mark GjomarkajMGMark Gjomarkaj
- 9 March 2011
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 48 (4) , 387-392
Abstract
Rationale. Severe asthma is characterized by inadequate symptom control and by high rate of inflammation despite high doses of steroids. Omalizumab, a recombinant humanized monoclonal anti-IgE, provides a new therapeutic strategy in severe allergic asthma. Aims. This study was aimed to assess whether long-term treatment with omalizumab improved clinical control in severe asthmatics. Methods. We investigated omalizumab effects on asthma outcomes evaluating seven severe allergic asthmatic patients who were treated for 7 years with add-on omalizumab. Number of exacerbations, use of antibiotics, additional asthma medications (systemic steroids, nebulized steroids and bronchodilators), and spirometry were analyzed before and after omalizumab treatment. Results. Omalizumab was well tolerated by all the studied patients. It improved FEV1 and FEV1/FVC ratio and reduced symptom score, asthma exacerbations, use of antibiotics, and use of nebulized steroids, bronchodilators, and oral corticosteroids. These effects were evident after 4 years of treatment and more pronounced after 7 years of treatment. Conclusions. This study underlines the utility of a long-term treatment with omalizumab to improve asthma clinical outcomes in severe asthmatics.Keywords
This publication has 27 references indexed in Scilit:
- Anti-inflammatory effects of seven years treatment with Omalizumab in severe uncontrolled asthmaticsAllergy, 2010
- Non‐invasive markers of airway inflammation and remodeling in childhood asthmaPediatric Allergy and Immunology, 2009
- Bugs and Asthma: A Different Disease?Proceedings of the American Thoracic Society, 2009
- Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti‐IgE treatmentAllergy, 2008
- Variable p‐CREB expression depicts different asthma phenotypesAllergy, 2007
- Asthma exacerbations {middle dot} 4: PreventionThorax, 2006
- Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthmaJournal of Allergy and Clinical Immunology, 2006
- Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-γ–inducible protein 10 expression in asthmatic airway mucosaJournal of Allergy and Clinical Immunology, 2005
- Omalizumab rapidly decreases nasal allergic response and FcεRI on basophilsJournal of Allergy and Clinical Immunology, 2004
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999